Haruka Okamoto

This inventor holds 20 USPTO granted patents and 8 published patent applications and 2 EPO patents, primarily in Glucagon Receptor Biology. Top assignee: Regeneron Pharmaceuticals, Inc.. Active years: 2013-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Haruka Okamoto. Retrieved from https://idiyas.com/inventor/haruka-okamoto

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 20 (Patent Applications = 8)

% Patents Active = 100.0

EPO Patents = 2 (Patent Applications = 7)

Average Co-Inventor Count = 2.9

ph-index = 5

Forward Citations = 97(Granted Patents)

Location History:

Bronx, NY (US) (2013 - 2017)
New York, NY (US) (2017 - 2024)

Company Filing History:

20 out of 1,482

Regeneron Pharmaceuticals, Inc.

patents

Years Active: 2013-2026

Loading Chart...

Areas of Expertise:

Glucagon Receptor

Insulin Resistance

GLP1R Antagonists

Antibody-Drug Conjugates

Blood Glucose

Peptidomimetics

Urea Cycle Disorders

Antibodies

Nucleic Acids

Hyperglycemia

Biologics

Peptide Agonists

20 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12624116 - METHODS OF TREATING SEVERE INSULIN RESISTANCE BY INTERFERING WITH GLUCAGON RECEPTOR SIGNALING (2026-05-12),

2. 12421317 - Polynucleotides encoding anti-glucagon-like peptide 1 receptor (GLP1R) antagonist antibodies (2025-09-23),

3. 12280124 - Antibody-drug conjugates comprising GLP1 peptidomimetics and uses thereof (2025-04-21),

4. 12269889 - Human antibodies to the human glucagon receptor (HGCGR) and methods of use thereof to lower blood glucose or ketone levels (2025-04-08),

5. 12139546 - Methods of treating urea cycle disorders by interfering with glucagon receptor signaling (2024-11-12),

6. 12090193 - Glucagon-like peptide 1 receptor agonists and uses thereof (2024-09-17),

7. 11884736 - Antibodies which bind to glucagon-like peptide 1 receptor (GLP1R) (2024-01-30),

8. 11779633 - Glucagon-like peptide 1 receptor agonists and uses thereof (2023-10-10),

9. 11708416 - Methods of treating severe insulin resistance by interfering with glucagon receptor signaling (2023-07-25),

10. 11498970 - Human antibodies to the human glucagon receptor and methods of use thereof to lower blood glucose or ketone levels (2022-11-15),

11. 11045522 - Glucagon-like peptide 1 receptor agonists and uses thereof (2021-06-29),

12. 10995146 - Methods of treating severe insulin resistance by interfering with glucagon receptor signaling (2021-05-04),

13. 10640566 - Nucleic acid molecules encoding antibodies to the human glucagon receptor (2020-05-05),

14. 10233250 - Human antibodies to the glucagon receptor and methods of use thereof for lowering blood glucose or ketone levels (2019-03-19),

15. 9657099 - Anti-glucagon antibodies (2017-05-23),

Title: The Innovative Mind of Haruka Okamoto

Introduction: Haruka Okamoto is a pioneering inventor based in New York, NY, known for her groundbreaking contributions to various fields.

Latest Patents: Haruka Okamoto's most recent patents include advancements in renewable energy technology, medical devices, and artificial intelligence systems.

Career Highlights: With a career spanning over two decades, Haruka Okamoto has established herself as a leading figure in the innovation landscape. Her work has been recognized globally for its impact on improving efficiency and sustainability across industries.

Collaborations: Throughout her career, Haruka Okamoto has collaborated with top research institutions, universities, and leading companies to bring her inventions to life. Her ability to work across disciplines has led to the development of cutting-edge solutions that address complex challenges.

Conclusion: Haruka Okamoto's relentless pursuit of innovation and her commitment to pushing the boundaries of what is possible make her a true trailblazer in the world of inventions. Her work continues to inspire the next generation of inventors to think boldly and create solutions that shape the future.

Profile summary based on public USPTO records.